All news

© Getty Images

Epsilogen completes first-ever IgE antibody clinical trial

By Isabel Cameron

Epsilogen, a leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, has published phase 1 data from the first ever clinical trial of an IgE antibody therapeutic in Nature Communications.

© Getty Images

ImmunoGen to develop next-generation ADCs with ImmunoBiochem

By Isabel Cameron

ImmunoGen, a biotech company focused on the development of antibody-drug conjugate (ADC) technology to treat cancer, has announced a multi-target license and option agreement to research novel, first-in-class ADCs with ImmunoBiochem, a biopharma firm...

© Getty Images

MaaT Pharma joins Microbiome Therapeutics Innovation Group

By Isabel Cameron

MaaT Pharma, a clinical-stage biotech company focused on the development of Microbiome Ecosystem Therapies (MET) dedicated to improving survival outcomes for patients with cancer, is now a member of Microbiome Therapeutics Innovation Group (MTIG).

© Getty Images

PrecisionLife identifies genetic risk factors for long COVID

By Isabel Cameron

PrecisionLife, a computational biology company driving precision medicine in complex chronic diseases, has announced the results of its long COVID study, providing the first detailed genetic insights into the condition and its commonalities with other...

© Getty Images

Gene sequencing identifies rare pediatric disorders in Mexico

By Isabel Cameron

A new genetic sequencing technology from Element Biosciences has helped researchers from the Translational Genomics Research Institute (TGen), part of the City of Hope, identify the likely genetic causes of disorders in six of nine children from Sonora,...

© Getty Images

Sosei Heptares doses first patient in schizophrenia drug trial

By Isabel Cameron

Sosei Heptares has dosed the first subject in a phase 1 trial evaluating HTL’149, a first-in-class GPR52 agonist, which represents a novel mechanism of action for the treatment of schizophrenia and related neurological diseases.

© Getty Images

First patient dosed in Enterome’s metastatic colon cancer trial

By Isabel Cameron

Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases, has announced that the first patient has been dosed in its phase 1/2 trial evaluating EO4010.

© Getty Images

Donaldson acquires Univercells Technologies for €136 million

By Isabel Cameron

Donaldson, a provider of filtration products and solutions, has acquired Univercells Technologies, a producer of biomanufacturing solutions for cell and gene therapy research, development, and commercial manufacturing, to broaden its life sciences reach....